MAPK12 and diffuse large B-cell lymphoma: Multivariate analysis further confirmed that IPI score (p = 0.014), MAPK12 expression (p = 0.040), and the use of rituximab (p = 0.028) were independently associated with OS in DLBCL patients (Table 2).